Guru Sonpavde, MD

Closing out their review of metastatic urothelial carcinoma management, panelists share what they most look forward to in the evolving treatment landscape.

Focused discussion on the optimal selection and use of antibody-drug conjugate therapies in patients with metastatic urothelial carcinoma.

Expert perspectives on treatment sequencing pathways in metastatic urothelial carcinoma, with deference to recent trial data for both IO and ADC therapies.

The panel reviews a clinical scenario of metastatic urothelial carcinoma where the patient is not eligible for cisplatin treatment.

A comprehensive review of maintenance therapy strategies following chemotherapy in the context of optimizing patient outcomes.

Centering discussion on a clinical scenario of metastatic urothelial carcinoma, panelists determine which first-line regimen they would utilize prior to maintenance therapy.

A panel of experts reviews key clinical trial data supporting use of maintenance therapy in metastatic urothelial carcinoma.

Shared insight on the broader benefits of maintenance therapy in metastatic urothelial carcinoma and the mainstay agents in this setting.

Expert oncologists provide a comprehensive overview of treatment options available to patients with metastatic urothelial carcinoma.

A brief review of both neoadjuvant and adjuvant treatment options available to patients with localized bladder cancer.

Opening their discussion on urothelial carcinoma management, panelists highlight risk factors, symptoms, and staging practices in this setting.

Experts highlight emerging data and novel regimens that have the biggest potential to impact treatment and management of patients with urothelial cancer.

Experts comment on the utility of PARP inhibitors in UC and discuss data presented at ASCO GU 2022.

Guru Sonpavde, MD, introduces emerging antibody-drug conjugates for treating metastatic UC, and reviews recent ASCO GU 2022 data on these regimens.

Petros Grivas, MD, PhD, transitions the panel discussion to focus on clinical trial data on combination immunotherapy versus platinum chemotherapy regimens that were recently presented at ASCO GU 2022.

The panel summarizes unmet needs in frontline maintenance therapy for UC and comments on ongoing trials for novel treatment regimens.

Petros Grivas, MD, PhD, revisits the patient profile and invites panel members to share recommended treatment options for patients with or without FGFR mutations, who progress after chemotherapy and maintenance avelumab.

Experts comment on the typical urothelial cancer maintenance therapy duration in their practice, and situations in which they might consider interrupting treatment while maintaining patient response.

Petros Grivas, MD, PhD, shares a clinical scenario of a cisplatin-ineligible patient with high PD-L1 expression and lymph node metastases, and experts weigh in on recommended treatment options.

Panel members share insights into strategies and barriers to maintenance therapy for patients with bladder cancer.

Thomas Powles, MBBS, MRCP, MD, comments on patient-reported outcome data and quality of life data in patients receiving maintenance therapy for metastatic urothelial cancer.

Thomas Powles, MBBS, MRCP, MD, discusses recent data from the JAVELIN Bladder 100 trial on maintenance avelumab therapy plus best supportive care versus BSC alone.

Experts discuss the role of biomarkers in treatment selection for patients with metastatic UC.

Petros Grivas, MD, PhD, introduces a patient profile of a woman with metastatic UC and invites panel members to comment on how they might approach initial treatment and management of the patient.

Petros Grivas, MD, PhD, Shilpa Gupta, MD, Peter H. O’Donnell, MD, Thomas Powles, MBBS, MRCP, MD, and Guru Sonpavde, MD, summarize recent treatment advances for patients with urothelial cancer (UC).

CancerNetwork® recap of an Around the Practice event with Neeraj Agarwal, MD, Petros Grivas, MD, PhD, Guru Sonpavde, MD, Thomas Powles, MBBS, MD, MRCP

Thomas Powles, MBBS, MRCP, MD, leads the discussion on selecting chemotherapy vs immune checkpoint inhibitors in the adjuvant setting for a patient who has metastases in urothelial carcinoma as well as approaching therapy for variant histology.

Guru P. Sonpavde, MD, leads the discussion on the use of adjuvant nivolumab in metastatic urothelial carcinoma and the impact on the subsequent use of immune checkpoint inhibitors in recurrent disease.

Petros Grivas, MD, PhD; Guru P. Sonpavde, MD; Thomas Powles, MBBS, MRCP, MD; and Neeraj Agarwal, MD, comment on the role of biomarker testing and its impact on the patient selection and approach to treatment for advanced urothelial carcinoma.

Experts in bladder cancer discuss when it’s appropriate to use avelumab maintenance therapy both with and without progression of disease in advanced urothelial cancer.